Patients and methods The serotonin receptor blocker ketanserin was given orally in a double blind crossover study to During the study, which was conducted from March to June, the patients received no drugs other than ketanserin or placebo. During the initial week all patients received placebo tablets three times a day and were then randomly assigned to either ketanserin or placebo in a double blind crossover study lasting nine weeks. The first treatment period lasted three weeks and was followed by a washout period of three weeks when the patients were taking placebo, and then followed by the second treatment period. The dose of ketanserin was 20 mg three times a day; after 10 days this dose (and that of placebo) was doubled in nine of the 10 patients, to 40 mg ketanserin three times a day. The other patient complained of dizziness and refused to double the dose. When we broke the code at the end of the trial, we found that she had been on ketanserin in that period.
Patients and methods The serotonin receptor blocker ketanserin was given orally in a double blind crossover study to 10 patients with connective tissue disorders and Raynaud's phenomenon. Eight of the 10 patients improved clinically on ketanserin and none on placebo. Digital blood flow was assessed with laser Doppler flowmetry (LDF), photoplethysmography, and skin temperature measurements. Laser Doppler flowmetry was the most useful method, showing a significant reduction in recovery time after a standard cold provocation. Although the resting flow was not significantly improved, digital ulcers healed in four out of five patients, providing evidence of increased nutritive flow.
The results of this study suggest that orally administered ketanserin may be an effective and well tolerated treatment for Raynaud's phenomenon associated with connective tissue disorders, especially scleroderma.
ntroduction Patients with connective tissue disorders, particularly scleroderma, often present with Raynaud's phenomenon and some with ischaemic ulcers on their fingertips. The pathogenesis of Raynaud's phenomenon and scleroderma is unknown, and effective treatment is lacking. Serotonin may be a causal factor in peripheral vasoconstrictive diseases, particularly in scleroderma.1-3 It causes platelet aggregation and pulmonary hypertension and is a potent vasoconstrictive agent which also amplifies constriction induced by noradrenaline and cooling. 4 6 In a previous study we found that the serotonin receptor antagonist ketanserin, given intravenously, increased digital temperature and blood flow in patients with Raynaud's phenomenon." The purpose of the present study was to compare the effect of orally administered ketanserin with that of placebo in patients with scleroderma and Raynaud's phenomenon. During the study, which was conducted from March to June, the patients received no drugs other than ketanserin or placebo. During the initial week all patients received placebo tablets three times a day and were then randomly assigned to either ketanserin or placebo in a double blind crossover study lasting nine weeks. The first treatment period lasted three weeks and was followed by a washout period of three weeks when the patients were taking placebo, and then followed by the second treatment period. The dose of ketanserin was 20 mg three times a day; after 10 days this dose (and that of placebo) was doubled in nine of the 10 patients, to 40 mg ketanserin three times a day. The other patient complained of dizziness and refused to double the dose. When we broke the code at the end of the trial, we found that she had been on ketanserin in that period.
Each day the patients wrote down the frequency, duration, and severity of Raynaud attacks. Severity was assessed by symptom scores: 1 =typical colour changes, 2=colour changes and numbness, 3 =colour changes, numbness, and pain. The patients evaluated the effect on symptoms during the three periods according to the following scale: 1=excellent, 2=good, 3=no change, 4=worse. Every tenth day blood pressure, pulse rate, changes in digital ulcers, side effects, and patients' scores for drug effectiveness were recorded, as well as other changes related to their systemic illness. A complete blood count and biochemical analysis of renal and hepatic function were performed every three weeks.
To show microcirculatory effects, the patients were examined with laser Doppler flowmetry to measure relative erythrocyte flux (Periflux, Sweden), with photoplethysmography to measure pulsatile flow, and with skin temperature recordings.6 Skin temperature was measured on the pulp of index finger, flowmetry was performed on the volar aspect of the second phalanx of the third finger, and photoplethysmography was performed on the pulp of the fourth finger. Room temperature was 23-25'C. The last medication was taken one to two hours before the measurements. The patients rested for 30 minutes in the supine position, and signals were then recorded continuously for five minutes before the hand was cooled in a water bath at 15'C for two minutes and carefully dried with a towel. Recovery time for erythrocyte flux, pulsatile flow, and skin temperature was then measured (fig 1) . Because erythrocyte flux often did not reach its precooling level even after one hour, the recovery of digital circulation was defined at the point where characteristic spikes reappeared in the laser Doppler flowmetry tracings.
All patients were examined at the end of the two treatment periods and the washout period, and the same digits were used on 
Results
During treatment with ketanserin the effect on symptoms was rated as good or excellent by eight of the 10 patients and as producing no change by two. None reported any change on placebo (p< 0001). The number of vasospastic attacks per day were significantly reduced from an average of 4 (SD 0 9) on placebo, to an average of 1-2 (0 3) attacks on ketanserin (p<0 05). Photoplethysmography recordings of the recovery time of pulsatile flow corresponded well with the flowmetry results in three patients but could not be used in the other patients because of inadequate signals.
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Temperature recovery was prolonged compared with the other variables, and therefore only 500' recovery was measured, but there was no significant reduction on ketanserin.
The side effects reported were transient dizziness in three patients on ketanserin and one on placebo. No significant changes were seen in blood pressure, pulse rate, or haematological or biochemical variables.
Discussion
Oral administration of ketanserin significantly reduced the number and the duration of Raynaud attacks as well as the duration of cold provoked attacks measured with laser Doppler flowmetry. The effect on symptoms was rated as good or excellent by eight of the 10 patients, who one year after the trial still take the drug daily. These findings correlate well with our previous results and suggest that ketanserin acts by blocking the platelet aggregation and vasoconstriction induced by serotonin.9
In higher doses the drug has a weak a,-adrenolytic effect which may contribute to the vasodilatating effect of the serotonin receptor blockade.10 The drug also improves red cell deformability, which is reduced in scleroderma, and several studies have indicated that serotonin plays a part in the pathogenesis of the vascular changes.3 11 A serotonin blocking agent such as ketanserin may therefore possibly relieve circulatory disturbances in patients with scleroderma.
Morphological studies of digital pulp in patients with scleroderma have shown involution of arteriovenous anastomoses and capillary abnormalities.'2 These changes may reduce both nutritive and non-nutritive blood flow. Digital blood flow has been assessed by several methods. The xenon washout technique probably measures only capillary flow while laser Doppler flowmetry and photoplethysmography seem to measure flow in both digital capillaries and arteriovenous anastomoses."
We have registered blood flow levels and recovery time after a standard cold provocation using erythrocyte-flux measured by flowmetry, pulsatile flow measured by photoplethysmography, and skin temperature as indices. Photoplethysmography could not be performed in several patients, possibly because of the tightness of the skin and low digital blood flow in scleroderma, with a resulting low pulsatile flow. Laser Doppler flowmetry proved to be the best method of estimating the variation in digital blood flow in this group of patients. As an indication of increased nutritive blood flow, digital ulcers healed in four out of five patients during oral ketanserin treatment, although no significant increase in erythrocyte flux could be shown by flowmetry. Now that we know that digital blood flow increases after ketanserin injections and that the drug is well tolerated, further studies with higher doses and longer periods of treatment are warranted to determine the precise role of ketanserin in the treatment of Raynaud's phenomenon. reviewed 18 patients and found two cases of polyuria and polydipsia, one of which was transient. 8 Haddock et al found two cases of transient polyuria and polydipsia among 50 patients. 9 There has never been a systematic study of antidiuretic function in Sheehan's syndrome and we therefore attempted to investigate a homogeneous series of patients. We report the data obtained using the combined dehydration and argininevasopressin test.
Subjects and methods
Twenty patients with the characteristic clinical picture of panhypopituitarism of slow onset after haemorrhagic delivery were included in the study. Total failure of the anterior pituitary was confirmed by a combined luteinising hormone releasing hormone-thyrotrophin releasing hormone-insulin stimulation test. Blood samples were collected every 20 minutes for two hours for determination of follicle stimulating hormone, luteinising hormone, thyroid stimulating hormone, prolactin, growth hormone, cortisol, and adrenocorticotrophic hormone (ACTH) concentrations. In addition, corticotrophin deficiency was confirmed by a lack of response of the plasma ACTH concentration and urinary 1 7-hydroxycorticosteroid excretion to metyrapone administration. Other causes of hypopituitarism were ruled out by the history, results of physical examination, laboratory findings, and radiological evidence. To eliminate the effect of thyroid or adrenal insufficiency all the patients were treated with hydrocortisone and thyroid hormones and return to normal was confirmed by assay of serum cortisol and thyroid hormone values.
The mean age of the patients was 35 3 years (range 21-42) and the average interval since the onset of their disease 7 5 years (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Results were compared with those in 12 normal women (mean age 29 5 years, range 22-42).
PROTOCOL
The dehydration tests was conducted using the procedure of Miller et al. 10 11 All subjects were deprived of food and water from 7 pm on the evening before the test. Urinary flow and osmolality were measured every hour from 8 am. Maximal urinary concentrating ability was assumed to be achieved when the osmolality did not change by more than 30 mmol (mosmol)/kg in three successive samples. A blood sample was then drawn for determination of serum osmolality and 20 timol desmopressin (DDAVP) given by intranasal spray. The effect of desmopressin on urine osmolality was estimated one hour after administration. If 
